A systematic review and network meta-analysis of second-line therapy in hepatocellular carcinoma

Current Oncology

View Publication Info
 
 
Field Value
 
Title A systematic review and network meta-analysis of second-line therapy in hepatocellular carcinoma
 
Creator Delos Santos, S.
Udayakumar, S.
Nguyen, A.
Ko, Y.J.
Berry, S.
Doherty, M.
Chan, K.K.W
 
Subject Liver cancer
regorafenib
cabozantinib
sorafenib
 
Description Background In patients with advanced hepatocellular carcinoma (hcc) following sorafenib failure, it is unclear which treatment is most efficacious, as treatments in the second-line setting have not been directly compared and no standard therapy exists. This systematic review and network meta-analysis (nma) aimed to compare the clinical benefits and toxicities of these treatments.
Methods A systematic review of randomized controlled trials (rcts) was conducted to identify phase iii rcts in advanced hcc following sorafenib failure. Baseline characteristics and outcomes of placebo were examined for het­erogeneity. Primary outcomes of interest were extracted for results, including overall survival (os), progression-free survival (pfs), objective response rate (orr), grade 3/4 toxicities, and subgroups. An nma was conducted to compare both drugs through the intermediate placebo. Comparisons were expressed as hazard ratios (hrs) for os and pfs, and as risk difference (rd) for orr and toxicities. Subgroup analyses for os and pfs were also performed.
Results Two rcts were identified (1280 patients) and compared through an indirect network; celestial (cabozantinib vs. placebo) and resorce (regorafenib vs. placebo). Baseline characteristics of patients in both trials were similar. Both trials also had similar placebo outcomes. Cabozantinib, compared with regorafenib, showed similar os [hazard ratio (hr): 1.21; 95% confidence interval (ci): 0.90 to 1.62], pfs (hr: 1.02; 95% ci: 0.78 to 1.34) and orr (−3.0%; 95% ci: −7.6% to 1.7%). Both treatments showed similar toxicities, but there were marginally higher risks of grade 3/4 hand–foot syndrome (5%; 95% ci: 0.1% to 9.8%), diarrhea (4.8%; 95% ci: 1.1% to 8.5%), and anorexia (4.4%; 95% ci: 0.8% to 8.0%) for cabozantinib. Subgroup results for os and pfs were consistent with overall results.
Conclusions Overall, this nma determined that cabozantinib and regorafenib have similar clinical benefits and toxicities for second-line hcc.
 
Publisher Multimed Inc.
 
Date 2020-08-09
 
Type info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
 
Format application/pdf
application/pdf
text/html
 
Identifier http://www.current-oncology.com/index.php/oncology/article/view/6583
10.3747/co.27.6583
 
Source Current Oncology; Vol. 27 No. 6 (2020)
1718-7729
1198-0052
 
Language eng
 
Relation http://www.current-oncology.com/index.php/oncology/article/view/6583/9623
http://www.current-oncology.com/index.php/oncology/article/view/6583/9515
http://www.current-oncology.com/index.php/oncology/article/view/6583/9677
 
Rights Copyright (c) 2020 Current Oncology
 

Contact Us

The PKP Index is an initiative of the Public Knowledge Project.

For PKP Publishing Services please use the PKP|PS contact form.

For support with PKP software we encourage users to consult our wiki for documentation and search our support forums.

For any other correspondence feel free to contact us using the PKP contact form.

Find Us

Twitter

Copyright © 2015-2018 Simon Fraser University Library